By targeting appetite regulation, glucose control, and energy balance, cagrilintide may represent an important step forward in managing obesity, type 2 diabetes, and related metabolic conditions ( 1, 3 )
CagriSema Dose Escalation Protocol The cagrilintide dosage with semaglutide follows its own escalation schedule, with both compounds increasing in tandem: The maintenance dose for CagriSema settles at cagrilintide 2.4 mg plus semaglutide 2.4 mg weeklynotably lower than the 4.5 mg monotherapy dose for cagrilintide
If needed, use a larger sterile vial or split volume appropriately
3f), and its relative abundance was lowest in WD control mice compared to all other groups
When to increase dose Consider increasing if: Minimal response after 4-6 weeks at current dose No side effects at current dose Current dose below the higher end of recommended range Goals not being met with conservative approach Increase gradually, typically by 25-50% at a time